Clinical trial
OGX-011 and Docetaxel in Treating Women With Locally Advanced or Metastatic…
NCT00258375 · NCIC Clinical Trials Group, Other · Completed
Key facts
| NCT number | NCT00258375 |
|---|---|
| Title | OGX-011 and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer |
| Official title | A Phase II Study of a Second Generation Clusterin Antisense Oligonucleotide (OGX-011) in Combination With Docetaxel in Advanced Breast Cancer |
| Lead sponsor | NCIC Clinical Trials Group, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | custirsen sodium, docetaxel |
| Enrollment | 15 |
| Start date | Oct 21, 2005 |
| Primary completion | Feb 23, 2007 |
| Completion | Sep 22, 2008 |
| First posted | Nov 24, 2005 |
| Last update posted | Aug 4, 2023 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: